A Post-marketing Observational Study of Cell Therapy for Chronic Wounds

Chronic wounds can be categorized into two main groups: (a) chronic ulcers, such as diabetic foot ulcers, venous leg ulcers and pressure (decubitus) ulcers (b) post-operative or traumatic, difficult-to-heal wounds, some of which may be infected such as sternal wound infections following cardiac surgery or wounds following abdominal or orthopedic surgery. Age, peripheral vascular disease, infection, diabetes mellitus, auto-immune dis., obesity, cardiac disease, cardiac failure, malnutrition, immunological deficiencies, steroid treatment, bed confinement and prolonged operation time are among the causes of wound repair delay or failure and often results in considerable morbidity and mortality. In addition, these wounds lengthen hospital stays, significantly increase the cost of care, and negatively impact the quality of life of both the patients and care giversCurrently available wound care products include various dressings, ointments, gels, antiseptic agents and devices. These products are intended to supply a suitable environment for wound healing (e.g. moist environment, particular factors required for the healing process), but they do not provide an adequate solution for this growing problem of chronic wounds.

Macrocure has developed an advanced cellular therapy for wound healing named Curexcell™. Curexcell™ not only provides the natural environment for wound healing, but also ensures that the appropriate cell activities and factor secretions are maintained as required during each of the stages of wound healing. The product contains primed/activated Monocytes, Neutrophils and Lymphocytes derived from whole blood unit, which are key role players in the normal natural wound healing process. The cells are injected locally into the wound bed.

The proposed study is a post-marketing observational study (PMOS) in which the decision to use Curexcell™ for treatment of patients with chronic and/or refractory wounds are made by local physicians. Curexcell™ will be administered to the patient in accordance with the Instructions for Use.

In this PMOS, there is no control by the investigator with respect to patients, duration and frequency of follow-up and the method by which patients are managed in general. This design truly reflects real-life circumstances.

Inclusion criteria

• Patients with chronic and/or refractory wounds that have been referred by their physician for CUREXCELLTM treatment
• Signed consent form

Inclusion criteria

FOR THE BLINDING GUESSING TEST

• Patients with chronic lower extremity ulcers (on malleoli and below) and diabetes mellitus
• Signed the blinding guessing test section of the consent form
• Were not treated in the past by CureXcell

Exclusion criteria

• Patients with known or suspected present malignancy (except for successfully treated basal cell carcinoma) within the past 3 years.
• Patients with gangrene
• Patients for whom amputation or a complete resection of the infection site is planned component of treatment
• Patients simultaneously participating in any interventional clinical trial
• Patients with any other known or suspected condition that may jeopardize adherence to registry protocol requirements